API Gallery
The Daprodustat market is predicted to increase at a 7.2% CAGR from 2025 to 2035, driven by the rising prevalence of anemia caused by chronic kidney disease (CKD) and the desire for oral alternatives to injectable erythropoiesis-stimulating agents (ESAs).
The Dapoxetine market is projected to grow at a CAGR of 6.5% from 2025 to 2035, driven by the growing demand for male sexual health solutions, particularly for premature ejaculation (PE), which is among the most prevalent male sexual disorders globally.
The Dapoxetine Hydrochloride market is anticipated to grow at a CAGR of 6.8% from 2025 to 2035, driven by rising awareness and demand for targeted male sexual health treatments, particularly for premature ejaculation (PE).
The Dapagliflozin market is projected to grow at a CAGR of 7.1% from 2025 to 2035, fueled by its expanding therapeutic applications beyond glycemic control.
The Dapagliflozin Propanediol market is anticipated to grow at a CAGR of 7.6% between 2025 and 2035, driven by its pivotal role in the formulation of SGLT2 inhibitors used for treating Type 2 Diabetes Mellitus, Heart Failure, and Chronic Kidney Disease (CKD).
The Dapagliflozin Propanediol Monohydrate market is projected to grow at a CAGR of 7.9% from 2025 to 2035, driven by the API’s critical role in SGLT2 inhibitor therapies.
The Crotamiton market is projected to grow at a CAGR of 5.4% during the forecast period 2025–2035. This growth is mainly driven by the increasing prevalence of parasitic skin infections and the increasing incidence of chronic pruritus (itching conditions), especially in the elderly and immunocompromised populations.
The Codeine market is projected to grow at a CAGR of 4.7% from 2025 to 2035, fueled by its enduring role in treating mild to moderate pain and as an effective antitussive in cough suppressants. As a naturally derived opioid, codeine remains one of the most commonly used s for its balanced efficacy and relatively mild side effect profile.
The Ceftizoxime Sodium market is anticipated to grow at a CAGR of 4.6% between 2025 and 2035, propelled by its increasing role in the treatment of moderate to severe bacterial infections where injectable cephalosporins are preferred.
The Ceftiofur Sodium API market is projected to grow at a CAGR of 6.0% from 2025 to 2035, primarily driven by its critical role in the treatment of respiratory and systemic infections in livestock, particularly in bovine and swine populations.
The Ceftiofur Hydrochloride (HCl) market is anticipated to grow at a CAGR of 5.9% from 2025 to 2035, propelled by the rising prevalence of infectious diseases in livestock and the increased global demand for safe, residue-free veterinary antibiotics.
The Ceftazidime market is predicted to develop at a CAGR of 5.9% between 2025 and 2035, owing to its broad-spectrum efficacy against infections such as septicemia, and respiratory, and urinary tract infections, particularly in critical care environments.
The Ceftaroline Fosamil API market is expected to increase at a CAGR of 6.7% between 2025 and 2035, owing to the increasing prevalence of drug-resistant Gram-positive infections, particularly MRSA.
The Cefradine API market is projected to grow at a CAGR of 4.8% from 2025 to 2035, driven by its affordability, broad-spectrum efficacy, and continued demand for first-generation cephalosporins in treating respiratory, urinary, and skin infections—especially in low- and middle-income countries.
The Cefquinome Sulfate market is projected to grow at a CAGR of 6.3% from 2025 to 2035, driven by rising demand for broad-spectrum veterinary antibiotics in livestock care.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
